List of Excipients in Branded Drug PHOSLO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Physicians Total Care Inc	PHOSLO	calcium acetate	54868-5691	D&C RED NO. 28
Physicians Total Care Inc	PHOSLO	calcium acetate	54868-5691	FD&C BLUE NO. 1
Physicians Total Care Inc	PHOSLO	calcium acetate	54868-5691	GELATIN

PHOSLO Excipient Strategy and Commercial Opportunities

Last updated: August 11, 2026

PhosLo is a calcium acetate phosphate binder used to control hyperphosphatemia in patients with end-stage renal disease. Its commercial opportunity is primarily generic and formulation-driven because calcium acetate is an old, chemically simple active ingredient with limited product-specific patent protection. The strongest opportunities are lower-cost oral solid dosage forms, improved swallowability, moisture-stable tablets or capsules, dialysis-center supply contracts, and differentiated adherence products.

What is PhosLo and how does it work?

PhosLo contains calcium acetate, a calcium-based phosphate binder. The active ingredient binds dietary phosphate in the gastrointestinal tract and reduces phosphate absorption. The labeled strength of the PhosLo Gelcap is 667 mg calcium acetate, equivalent to approximately 169 mg elemental calcium per capsule.[1]

Attribute	PhosLo
Active ingredient	Calcium acetate
Therapeutic category	Phosphate binder
Primary use	Hyperphosphatemia in end-stage renal disease
Dosage form	Oral capsules or gelcaps; calcium acetate tablets are also marketed generically
Standard labeled strength	667 mg calcium acetate
Elemental calcium per unit	Approximately 169 mg
Administration	With meals
Regulatory pathway for competitors	Generally ANDA under section 505(j)
Biosimilar relevance	None
Main commercial alternatives	Sevelamer, lanthanum carbonate, sucroferric oxyhydroxide, ferric citrate

PhosLo is administered with meals because its value depends on binding phosphate in the gastrointestinal tract at the time food is present. This creates a formulation challenge: the product must be inexpensive, easy to swallow, physically stable, and capable of rapid and reproducible release.

What excipients are used in PhosLo formulations?

The precise excipient profile depends on the manufacturer, dosage form, and current product label. PhosLo Gelcaps have historically used a gelatin capsule shell with conventional pharmaceutical processing excipients and colorants.[1] Generic calcium acetate products may use different capsule, tablet, coating, lubricant, disintegrant, and glidant systems.

Common excipient categories include:

Excipient function	Potential materials	Commercial purpose
Capsule shell	Gelatin or hypromellose	Unit-dose delivery and swallowability
Diluent	Microcrystalline cellulose, lactose-free fillers, dibasic calcium phosphate where compatible	Controls tablet weight and manufacturability
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule and tablet strength
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Supports rapid breakup after administration
Lubricant	Magnesium stearate, sodium stearyl fumarate	Prevents sticking and improves ejection
Glidant	Colloidal silicon dioxide	Improves powder flow
Capsule colorant	Titanium dioxide or approved colorants	Product identification and branding
Film coating	Hypromellose, polyethylene glycol, mineral or synthetic pigments	Appearance, identification, handling
Moisture-control packaging	High-barrier blister, desiccant bottle, induction seal	Protects against humidity and dose variability

A formulation developer should not assume that an excipient is acceptable merely because it appears in another oral solid product. Each excipient must be assessed against FDA inactive-ingredient precedent, route, maximum daily exposure, product strength, and the proposed dosage form.[2]

Which excipient attributes matter most for calcium acetate?

Moisture stability

Calcium acetate products can present manufacturing and storage issues related to powder flow, caking, capsule filling, and tablet hardness. A moisture-control strategy should be established early.

Key controls include:

• Low-moisture raw materials
• Controlled relative humidity during blending and encapsulation
• High-barrier primary packaging
• Water-activity testing
• Stability testing under ICH long-term and accelerated conditions
• Evaluation of capsule brittleness and shell deformation
• Monitoring of dissolution after humidity exposure

A hard gelatin capsule may be commercially attractive because it avoids compression development, but it can create higher sensitivity to humidity and shell performance. A tablet can offer lower packaging and unit-cost economics, but it requires stronger control of compression force, friability, disintegration, and sticking.

Rapid and reproducible release

Calcium acetate is intended to act locally in the gastrointestinal tract. A formulation should therefore prioritize consistent disintegration and dissolution rather than extended release.

The development target should include:

• Consistent assay across the unit
• Low tablet-to-tablet weight variability
• Rapid disintegration
• Reproducible dissolution across relevant pH conditions
• Stable performance after storage
• No meaningful impact from capsule shell or film coating

A formulation that slows release without a clinical rationale may increase regulatory and bioequivalence risk. For an ANDA, the product must demonstrate pharmaceutical equivalence and bioequivalence to the reference product under FDA requirements.[3]

Elemental-calcium consistency

The commercial label is based on calcium acetate strength and elemental calcium exposure. Excess calcium exposure is clinically relevant because calcium-based phosphate binders can contribute to hypercalcemia and vascular or soft-tissue calcification concerns. KDIGO guidelines recommend managing calcium exposure and avoiding inappropriate calcium loading in patients with chronic kidney disease.[4]

Excipient selection should therefore protect dose uniformity and prevent calcium acetate from being diluted, segregated, or chemically altered during processing. Formulation changes that alter the delivered calcium dose or release behavior can create clinical and regulatory complications.

Swallowability and pill burden

Dialysis patients may take multiple phosphate-binding units with each meal. Swallowability is a commercial differentiator even when the active ingredient is generic.

Potential approaches include:

• Smaller, higher-density tablets
• Low-friction capsule shells
• Smooth film coatings
• Reduced tablet mass
• Unit-dose meal packs
• Patient-friendly blister formats
• Products designed for use with dialysis-center medication routines

Any reduction in unit size must preserve the labeled calcium acetate dose. A smaller tablet achieved by high compression or excessive density may become harder to disintegrate or swallow.

What formulation opportunities exist for PhosLo competitors?

Moisture-stable tablets

A moisture-stable immediate-release tablet is the clearest conventional opportunity. The objective is to reduce manufacturing cost and improve shelf stability while maintaining rapid release.

Potential development advantages include:

• Lower capsule-shell cost
• More efficient high-speed compression
• Easier imprinting and identification
• Better suitability for blister packaging
• Reduced risk of capsule-shell supply disruption

The main risks are sticking, capping, variable hardness, and dissolution changes caused by compression or coating.

Hypromellose capsules

Hypromellose capsules can be considered where a sponsor wants a vegetarian or gelatin-free positioning. They may also support supply-chain diversification. The product must demonstrate acceptable fill weight, shell compatibility, dissolution, and stability.

The commercial value is likely greater in institutional, specialty-pharmacy, or patient-preference channels than in a purely lowest-price generic tender.

Reduced-pill-burden presentations

A higher-strength unit could reduce the number of capsules or tablets per meal. This approach carries dose-size and swallowability constraints. It also increases the amount of active ingredient per unit and can make content uniformity, mechanical strength, and packaging more demanding.

A larger unit is commercially useful only if patients can swallow it and the formulation retains rapid release.

Adherence-oriented packaging

Packaging is an underdeveloped opportunity in phosphate binders. Possible products include:

• Breakfast, lunch, and dinner blister cards
• Dialysis-day versus non-dialysis-day packs
• Calendarized monthly cartons
• Pharmacy-ready unit-dose packs
• Meal-linked reminder packaging
• Institutional dispensing configurations

Packaging does not generally create strong patent protection by itself, but it can support contracting, brand differentiation, and pharmacy substitution resistance.

Pediatric or specialty formulations

Pediatric chronic kidney disease is a smaller market and may justify a liquid, powder, or dispersible formulation. The development burden is higher because calcium acetate suspension stability, palatability, dose uniformity, sedimentation, and measuring-device accuracy must be demonstrated.

A liquid formulation may have limited commercial value unless it addresses a defined swallowing or feeding-tube need. Calcium loading and dosing errors would be important labeling and safety concerns.

What regulatory pathway applies to a new PhosLo formulation?

ANDA pathway for generic calcium acetate

A conventional calcium acetate product that matches the reference product in active ingredient, dosage form, strength, route, and labeling would generally pursue an ANDA. The applicant must establish pharmaceutical equivalence and bioequivalence and comply with current good manufacturing practices.[3]

For an immediate-release oral product, excipient changes are usually manageable when they do not alter performance or raise safety concerns. The applicant must still demonstrate:

• Assay and content uniformity
• Impurity control
• Dissolution
• Stability
• Microbiological quality where applicable
• Container-closure suitability
• Manufacturing process control

505(b)(2) pathway

A 505(b)(2) application could be relevant to a materially differentiated formulation, such as a new route, a clinically meaningful dosage form, or a product that cannot rely fully on the reference product’s safety and effectiveness information.

A 505(b)(2) strategy generally has a higher development burden than an ANDA. It is commercially rational only when the formulation provides a defensible benefit, such as improved administration for a defined population or a clinically relevant reduction in pill burden.

FDA inactive-ingredient considerations

The FDA Inactive Ingredient Database is an important screening tool, but it is not a substitute for product-specific formulation and safety review.[2] A sponsor should examine:

• Maximum daily exposure of each excipient
• Precedent in oral solid dosage forms
• Use in chronic renal disease populations
• Potential gastrointestinal effects
• Compatibility with calcium acetate
• Colorant and capsule-shell requirements
• Excipient exposure at the maximum labeled dose

What patents protect PhosLo?

PhosLo has limited apparent current patent leverage compared with newer phosphate binders. Calcium acetate is an established small-molecule active ingredient, and generic calcium acetate products can generally compete through the ANDA pathway.

The relevant protection categories are:

Protection category	Relevance to PhosLo
Active-ingredient patent	Limited practical relevance for an old active ingredient
Core formulation patent	Potentially relevant only if a specific differentiated formulation remains enforceable
Method-of-use patent	Limited opportunity because the phosphate-binding use is established
Packaging patent	Possible but generally narrow
Manufacturing process patent	Possible, but often better protected as a trade secret
Trademark	Brand protection may remain separate from technical exclusivity
Regulatory exclusivity	No biosimilar-style exclusivity applies

The FDA Orange Book should be checked for current listed patents associated with the specific reference product and NDC. Publicly available product information does not indicate a major current Orange Book barrier comparable with patented branded products in newer therapeutic categories.[5]

When does PhosLo lose exclusivity?

PhosLo’s principal commercial exclusivity is not expected to be driven by a current composition-of-matter patent or biologic exclusivity period. The product is exposed primarily to generic substitution, manufacturer pricing, contracting, and channel access.

A prospective competitor should evaluate:

1. Whether the reference product remains actively marketed.
2. Whether the relevant reference product is listed in the Orange Book.
3. Whether any patents are listed against the applicable dosage form.
4. Whether a Paragraph IV certification is required.
5. Whether the proposed product matches the reference formulation sufficiently for an ANDA.
6. Whether state substitution and pharmacy-channel dynamics favor a new supplier.

Are Paragraph IV challenges likely for PhosLo?

Paragraph IV litigation risk appears structurally low because calcium acetate is an old product and does not present the same patent density as modern branded therapies. If a listed patent existed, an ANDA applicant could challenge it through a Paragraph IV certification. In the absence of an enforceable listed patent, the principal barriers are technical, regulatory, manufacturing, and commercial rather than patent-based.

Potential litigation could still arise from:

• A formulation patent covering a specific excipient combination
• A manufacturing-process patent
• Trademark or trade-dress claims
• Product liability allegations
• Commercial disputes over reference-product status

A formulation patent for a routine calcium acetate tablet would face obviousness and lack-of-inventive-step risks unless it produced a measurable and unexpected benefit.

What patent strength does an improved PhosLo formulation have?

A basic excipient substitution generally has weak patent strength. A stronger formulation estate would require a defined technical result supported by comparative data.

More defensible claim themes could include:

• A narrow moisture-content range that improves shelf life
• A specific excipient ratio that prevents segregation
• A capsule or tablet architecture that reduces pill burden while maintaining rapid release
• A packaging system that preserves dissolution under high humidity
• A manufacturing process that delivers superior content uniformity
• A formulation with demonstrated stability across a clinically important storage range

The strongest evidence would compare the candidate against commercial calcium acetate products under accelerated humidity, dissolution, hardness, friability, and long-term stability testing. Claims should be tied to measurable performance rather than a generic list of excipients.

What commercial opportunities exist in the PhosLo market?

Generic supply and private label

The most direct opportunity is a low-cost calcium acetate product for retail, specialty pharmacy, hospital, and dialysis channels. Buyers are likely to prioritize:

• Reliable supply
• Consistent quality
• Competitive acquisition cost
• Simple substitution
• Packaging flexibility
• Low shortage risk

Private-label and authorized-generic arrangements may offer faster commercialization than building a consumer-facing brand.

Dialysis-center contracting

Dialysis providers and integrated renal-care organizations can influence product selection. A supplier with dependable delivery, unit-dose packaging, and pharmacy integration may gain share even without strong patent protection.

Formulation licensing

Licensing opportunities are more likely to involve:

• A validated tablet platform
• A low-moisture capsule process
• A high-barrier packaging system
• A differentiated adherence package
• A contract-manufacturing technology transfer

The commercial value of a formulation license depends on whether it lowers total cost or improves substitution resistance. An excipient change alone may not justify a royalty unless it solves a measurable manufacturing or stability problem.

Revenue exposure

Public company filings generally do not separate PhosLo revenue from broader generic, renal, or pharmaceutical portfolios. Standalone PhosLo revenue is therefore difficult to quantify from public disclosures. Market value should be modeled using prescription volume, units per prescription, payer mix, generic price erosion, dialysis-channel contracts, and the number of approved suppliers rather than relying on historical branded sales.

How does PhosLo compare with competing phosphate binders?

Product	Active ingredient	Calcium exposure	Pill burden	Generic or biosimilar pressure	Formulation opportunity
PhosLo	Calcium acetate	Yes	Often significant	Generic competition	Low-cost, smaller, moisture-stable oral solids
Renvela/Renagel	Sevelamer carbonate/hydrochloride	No calcium	Often significant	Generic competition for some presentations	Powder, tablet, and adherence formats
Fosrenol	Lanthanum carbonate	No calcium	Variable	Generic competition	Chewable and palatability improvements
Velphoro	Sucroferric oxyhydroxide	No calcium	Lower in some regimens	Branded protection and lifecycle management	Chewability and administration
Auryxia	Ferric citrate	No calcium, adds iron	Variable	Branded protection and formulation strategy	Iron exposure management and adherence

PhosLo’s competitive advantage is cost and familiarity. Its main clinical disadvantages are calcium exposure and the need to manage total calcium load. A formulation that improves adherence without increasing calcium exposure would have a clearer market proposition than a cosmetic excipient change.

What generic launch risks exist?

The main launch risks are:

• Reference-product availability and status
• Failure to match dissolution or dosage-form performance
• Moisture-related stability failures
• Tablet sticking or capsule-filling variability
• Inadequate packaging protection
• Price erosion after multiple ANDA approvals
• Weak access to dialysis and specialty-pharmacy channels
• Clinical concern over calcium loading
• Limited differentiation from existing generic products

The lowest-risk strategy is usually an immediate-release oral solid product using excipients with established FDA precedent, supported by high-barrier packaging and a cost-efficient manufacturing process.

Key Takeaways

• PhosLo is a calcium acetate phosphate binder with limited apparent current patent protection.
• The commercial opportunity is primarily generic supply, private label, dialysis contracting, and adherence-focused packaging.
• Moisture control, rapid disintegration, content uniformity, and capsule or tablet swallowability are the central excipient priorities.
• A conventional excipient substitution is unlikely to create strong patent protection without comparative performance data.
• An ANDA is the likely regulatory pathway for a conventional equivalent; a 505(b)(2) strategy would require meaningful product differentiation.
• Biosimilar competition is irrelevant because PhosLo is a small-molecule oral product.
• Calcium exposure remains the principal clinical limitation relative to non-calcium phosphate binders.
• Manufacturing know-how, packaging design, supply reliability, and contracting may provide more practical value than broad formulation patents.

FAQs

Can calcium acetate be formulated as a chewable PhosLo product?

Yes, but a chewable product would require evaluation of taste, mouthfeel, dose uniformity, tablet strength, disintegration, and patient acceptability. It could require a different regulatory strategy if it does not match the reference dosage form.

Is hypromellose a viable alternative to gelatin for PhosLo capsules?

Yes. Hypromellose can support a gelatin-free capsule strategy, but the sponsor must establish fill performance, shell compatibility, dissolution, stability, and appropriate FDA excipient precedent.

Does a smaller PhosLo tablet necessarily improve commercial value?

No. Smaller size can improve swallowability, but excessive density or compression can impair disintegration, increase manufacturing defects, or alter dissolution. The benefit must be demonstrated through comparative product-performance data.

Can packaging be patented for a calcium acetate product?

Potentially. A packaging patent is more defensible when the system produces a measurable technical benefit, such as improved stability, moisture protection, dose organization, or administration compliance. Broad calendar packaging claims are likely to face design-around risk.

Is a liquid calcium acetate product commercially attractive?

It may be attractive for patients unable to swallow tablets or capsules, but the formulation must address suspension uniformity, sedimentation, palatability, dosing accuracy, stability, and calcium-dose control. The market is narrower than the conventional oral solid segment.

References

1. DailyMed. (n.d.). PhosLo: Calcium acetate capsule prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

3. U.S. Food and Drug Administration. (2024). Abbreviated new drug application (ANDA) process. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda

4. Kidney Disease: Improving Global Outcomes. (2017). KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder. Kidney International Supplements, 7(1), 1-59. https://kdigo.org/guidelines/ckd-mbd/

5. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm